Myelin-Oligodendrocyte Glycoprotein (MOG) Antibodies, Serum
Test Overview
Clinical Utility
Many cases of Neuromyelitis Optica-spectrum disorders (NMOSD) are misdiagnosed as Multiple Sclerosis. As correct diagnosis is critical for prognosis, optimal treatment and prediction of relapse, initial testing for both Aquaporin 4 (AQP4) Antibodies and Myelin-Oligodendrocyte Glycoprotein (MOG) Antibodies is strongly recommended for new cases of NMOSD – see separate test listings. AQP4 antibodies are detected in about 80% of patients with NMO. Of these seronegative AQP-4 cases 7% will harbor MOG antibodies. Patients very rarely harbour both antibodies.
Method
Cell-based immunofluorescence assay (IFA)
Method Description
Indirect immunofluorescence using MOG-transfected HEK cells (fixed cell-based assay).
Result Included
Myelin-Oligodendrocyte Glycoprotein Antibodies (Anti-MOG)
Aliases/Synonyms
Anti-MOG; MOG Antibodies
Specimen
Specimen Type
SerumContainers
Preferred Containers
Red Top (no additive)
Acceptable Containers
Gold Top (SST)
Volume
Sample Volume
1 mL
Minimum Volume
0.5 mL
Collection & Handling
Handling Information
Separate as soon as possible. Store and send frozen.
Additional Information
Avoid repeat freeze/thaw cycles.
Stability
| Ambient | Refrigerated | Frozen |
|---|---|---|
| 6 hours | 14 days | 30 days |
Avoid repeat freeze/thaw cycles.
Rejection Criteria
| Criteria | Specification |
|---|---|
| Hemolysis | Gross |
| Lipemic | Gross |
Performance & Interpretation
Turnaround Time
9 days
Results
-
Myelin-Oligodendrocyte Glycoprotein Antibodies (Anti-MOG)Negative
Comment
Low Positive (1:10): Positive at 1:10 dilution and Negative at 1:100 dilution, indicating an endpoint titre that is between 1:10 and 1:100.
Clear Positive (1:100): Positive at 1:10 dilution and Positive at 1:100 dilution, indicating an endpoint titre that is greater than or equal to 1:100.
Referral Location
Canada
Interface & Setup
HL7 Interface Codes
| Order Code | Result Name | Result Codes | Units |
|---|---|---|---|
| MOG S | Anti MOG | 62783 |
Test Version
Last Updated
2024-08-29